We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma. Revenues came in at $735.9 million, beating the Zacks Consensus Estimate of $725.3 million. Revenues rose 20% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The reported number represents a change of +4.9% year over year. Revenues- Unituxin- U.S. $61.80 million versus the two-analyst average estimate of $49.86 million. Revenues- Adcirca: $4.70 million ...